Literature DB >> 18587620

The impact of perceived treatment assignment on smoking cessation outcomes among African-American smokers.

Janet L Thomas1, Hongfei Guo, Ian M Lynam, Joshua N Powell, Kolawole S Okuyemi, Carrie A Bronars, Jasjit S Ahluwalia.   

Abstract

BACKGROUND: The double-blind placebo-controlled design is commonly considered the gold standard in research methodology; however, subject expectation bias could subvert blinding.
OBJECTIVE: The primary aim of this study was to examine the impact of expectation bias. Specifically, we examined perceived treatment assignment on smoking cessation outcome rates among participants enrolled in a clinical trial of bupropion (150 mg SR, BID).
DESIGN: Analyses were conducted on data collected during "Kick It at Swope," a double-blind, placebo-controlled, randomized trial of 600 African-American smokers. Chi-square and multiple logistic regression analyses were used to examine the impact of perception of assignment on treatment effect and cotinine-verified smoking abstinence rates. PARTICIPANTS: Participants were predominantly middle-aged (mean 44.7, SD 11.2), African-American women (68.6%), who smoked 19 CPD (SD = 8.1). Most had completed at least a high school education or GED (51.6%), and 55% had a monthly family income <$1,800. MEASUREMENTS: At week 6 (end of treatment) and week 26 (end of study), participants were asked to report their perceived treatment group assignment. Self-reported abstinence (weeks 6 and 26) was confirmed using CO and cotinine biochemical verification.
RESULTS: After adjusting for actual treatment assignment, age and baseline cotinine, participants who perceived being assigned to bupropion vs. placebo were more likely to be abstinent at weeks 6 (OR = 2.07, 95% CI: 1.29 to 3.33, p = 0.002) and 26 (OR = 1.85, 95% CI: 1.05 to 3.24, p = 0.032).
CONCLUSIONS: Results support previous research that expectation bias associated with judgment of treatment assignment is a strong predictor of outcome and confirms this relationship in a smoking cessation trial using bupropion SR among African-American smokers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587620      PMCID: PMC2518039          DOI: 10.1007/s11606-008-0656-3

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  29 in total

Review 1.  Smoking cessation among African Americans: what we know and do not know about interventions and self-quitting.

Authors:  L L Pederson; J S Ahluwalia; K J Harris; G A McGrady
Journal:  Prev Med       Date:  2000-07       Impact factor: 4.018

2.  In randomized controlled trials, should subjects in both placebo and drug groups be expected to guess that they are taking drug 50% of the time?

Authors:  N A Desbiens
Journal:  Med Hypotheses       Date:  2002-09       Impact factor: 1.538

Review 3.  The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials.

Authors:  Marc Mooney; Thom White; Dorothy Hatsukami
Journal:  Addict Behav       Date:  2004-06       Impact factor: 3.913

4.  The placebo puzzle: putting together the pieces.

Authors:  Steve Stewart-Williams
Journal:  Health Psychol       Date:  2004-03       Impact factor: 4.267

Review 5.  The placebo effect: dissolving the expectancy versus conditioning debate.

Authors:  Steve Stewart-Williams; John Podd
Journal:  Psychol Bull       Date:  2004-03       Impact factor: 17.737

6.  Extended treatment with bupropion SR for cigarette smoking cessation.

Authors:  Joel D Killen; Stephen P Fortmann; Greer M Murphy; Chris Hayward; Christina Arredondo; Deann Cromp; Maria Celio; Laurie Abe; Yun Wang; Alan F Schatzberg
Journal:  J Consult Clin Psychol       Date:  2006-04

7.  Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.

Authors:  Jasjit S Ahluwalia; Kari Jo Harris; Delwyn Catley; Kolawole S Okuyemi; Matthew S Mayo
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

Review 8.  Placebo effects of tobacco smoking and other nicotine intake.

Authors:  Kenneth Perkins; Michael Sayette; Cynthia Conklin; Anthony Caggiula
Journal:  Nicotine Tob Res       Date:  2003-10       Impact factor: 4.244

9.  Psychological intervention and antidepressant treatment in smoking cessation.

Authors:  Sharon M Hall; Gary L Humfleet; Victor I Reus; Ricardo F Muñoz; Diane T Hartz; Roland Maude-Griffin
Journal:  Arch Gen Psychiatry       Date:  2002-10

10.  Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial.

Authors:  Caryn Lerman; Vyga Kaufmann; Margaret Rukstalis; Freda Patterson; Kenneth Perkins; Janet Audrain-McGovern; Neal Benowitz
Journal:  Ann Intern Med       Date:  2004-03-16       Impact factor: 25.391

View more
  11 in total

1.  Perceived medication assignment during a placebo-controlled laboratory study of varenicline: temporal associations of treatment expectancies with smoking-related outcomes.

Authors:  John B Correa; Bryan W Heckman; Nicole S Marquinez; David J Drobes; Marina Unrod; Richard G Roetzheim; Thomas H Brandon
Journal:  Psychopharmacology (Berl)       Date:  2014-01-10       Impact factor: 4.530

2.  Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis.

Authors:  Ben Colagiuri; Robert A Boakes
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

3.  CPAP or placebo-effect?

Authors:  Skai W Schwartz; Cynthia R Cimino; W McDowell Anderson
Journal:  Sleep       Date:  2012-12-01       Impact factor: 5.849

4.  Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy.

Authors:  Steffani R Bailey; Dalea M Fong; Susan W Bryson; Stephen P Fortmann; Joel D Killen
Journal:  J Subst Abuse Treat       Date:  2010-07-03

5.  Smokers' Treatment Expectancies Predict Smoking Cessation Success.

Authors:  Lisa M Fucito; Benjamin A Toll; Corey R Roos; Andrea C King
Journal:  J Smok Cessat       Date:  2014-08-27

6.  Randomized controlled trial examining expectancy effects on the accuracy of weight measurement.

Authors:  G R Dutton; K R Fontaine; A S Alcorn; J Dawson; P L Capers; D B Allison
Journal:  Clin Obes       Date:  2014-12-22

7.  Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo.

Authors:  Taneisha S Buchanan; Lisa Sanderson Cox; Janet L Thomas; Nicole L Nollen; Carla J Berg; Matthew S Mayo; Jasjit S Ahluwalia
Journal:  Nicotine Tob Res       Date:  2012-09-04       Impact factor: 4.244

8.  Antidepressants for smoking cessation.

Authors:  Seth Howes; Jamie Hartmann-Boyce; Jonathan Livingstone-Banks; Bosun Hong; Nicola Lindson
Journal:  Cochrane Database Syst Rev       Date:  2020-04-22

Review 9.  Antidepressants for smoking cessation.

Authors:  John R Hughes; Lindsay F Stead; Jamie Hartmann-Boyce; Kate Cahill; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08

10.  Influence of methylphenidate treatment assumptions on cognitive function in healthy young adults in a double-blind, placebo-controlled trial.

Authors:  Jean-Luc Mommaerts; Gerlinde Beerens; Lieve Van den Block; Eric Soetens; Sandrina Schol; Erwin Van De Vijver; Dirk Devroey
Journal:  Psychol Res Behav Manag       Date:  2013-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.